Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

82.97B

Market cap82.97B

Price-Earnings ratio

19.86

Price-Earnings ratio19.86

Dividend yield

0.45%

Dividend yield0.45%

Average volume

737.61K

Average volume737.61K

High today

—

High today—

Low today

—

Low today—

Open price

$801.76

Open price$801.76

Volume

0.00

Volume0.00

52 Week high

$821.11

52 Week high$821.11

52 Week low

$541.00

52 Week low$541.00

Stock Snapshot

With a market cap of 82.97B, Regeneron(REGN) trades at $805.93. The stock has a price-to-earnings ratio of 19.86 and currently yields dividends of 0.45%.

Regeneron(REGN) stock opened on 2026-08-18 at $801.76. The price climbed to — and dipped to —.

Regeneron(REGN) shares are trading with a volume of 0, against a daily average of 737.61K.

During the past year, Regeneron(REGN) stock moved between $541.00 at its lowest and $821.11 at its peak.

REGN News

TipRanks 1d

Regeneron price target raised to $824 from $641 at Leerink

Leerink analyst David Risinger raised the firm’s price target on Regeneron (REGN) to $824 from $641 and keeps a Market Perform rating on the shares. Unlock pow...

Simply Wall St 3d

Biohaven Could Be 73% Undervalued As Regeneron Deal Expands - simplywall.st

...

Nasdaq 4d

GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)

Key Points Amgen is developing a highly differentiated GLP-1 product. Regeneron has a pair of promising GLP-1 candidates in the pipeline. Both biotechs are p...

Analyst ratings

63%

of 30 ratings

Buy

63.3%

Hold

36.7%

Sell

More REGN News

TipRanks 6d

Regeneron Targets Cat Allergy Eye Relief With New Phase 3 Antibody Trial

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, mo...

Simply Wall St 7d

Regeneron Pharmaceuticals Following Earnings And Buybacks, Is The Valuation Case Still Intact?

Advertisement Regeneron Pharmaceuticals earnings, dividend and buybacks come into focus Regeneron Pharmaceuticals (REGN) has drawn investor attention after re...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.